CPA Issues Statement of Support for New Labor Tariff Action
New duties on imports from dozens of countries take effect this week, closing the gap left after the Supreme Court struck down the President’s earlier tariff authority.
New duties on imports from dozens of countries take effect this week, closing the gap left after the Supreme Court struck down the President’s earlier tariff authority.
Companies making goods from the Department of War (DoW) will now need much clearer visibility into their supply chains, especially if a product they make or buy includes critical minerals.
Trade structured to support production raises productivity, and rising productivity raises the incomes that fund consumption durably, out of earnings instead of borrowing. That is the only durable answer to the cost-of-living crisis: paychecks that can carry the price of housing, healthcare, and childcare.
For years, the most critical link in our drug supply chain — the upstream chemistry — has been invisible to our own regulators. A medicine finished in Europe is not necessarily a European medicine, and this rule finally begins to expose that fiction.
A new joint white paper finds that aluminum extrusion — the most capital-intensive step in frame production — must occur in the United States for solar module frames to qualify for the Section 45Y/48E domestic content bonus credit.
Last week, the White House declared an emergency under Section 318 of the Tariff Act of 1930 and suspended, for eight months, the collection of anti-dumping and countervailing duties on phosphate fertilizer from the Kingdom of Morocco.
The goods deficit for May is the worst looking deficit on paper, at $106.4 billion, but might not be as bad as that number suggests.
Before USTR borrows the tin cartel’s playbook, it should look to the American tradition of minimum import pricing — and beware the foreign imitations that ended in ruin.
Years ago, CPA warned that China was using American clean-energy tax credits to capture our solar industry — and we led the fight to slam that door shut.
Sen. Kirsten Gillibrand (D-NY) has become one of the Democratic Party’s leading voices raising concerns about the pharmaceutical industry’s growing ties to China.